QuatRx gains $125M licensing pact

QuatRx has scored a $125 million licensing deal with Shionogi. The Japanese company will pay $25 million of that upfront for the worldwide marketing rights to ospemifene for the treatment of post-menopausal vulvovaginal atrophy. And NDA is planned later this year. QuatRx release

Suggested Articles

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.

Johns Hopkins researchers developed a biodegradable polymer to transport large therapies into cells—including genes and even CRISPR.

UCB’s bispecific antibody recently beat Johnson & Johnson’s Stelara at clearing psoriasis symptoms, and now it has bested AbbVie’s Humira, too.